US EditionKenya Receives 21,000 Doses of Long-Acting HIV Prevention Drug Ahead of March Rollout
- On February 18, Kenya received an initial consignment of 21,000 starter doses of Lenacapavir, with Health Minister Aden Duale saying, `The first phase of implementation will begin early March, covering 15 counties`.
- Regulators backed lenacapavir—U.S. Food and Drug Administration approved in June 2025, WHO endorsed in July 2025, and Kenya registered it in January 2026 to support public health goals.
- Administered twice a year, Lenacapavir reduces transmission risk by more than 99.9% and will cost about Sh7,800 annually, down from roughly $42,000 previously.
- Dr Patrick Amoth received the shipment with Global Fund partners and U.S. Embassy-Kenya representative Brian Rettman; 12,000 continuation doses are expected by April and the United States Government committed 25,000 more.
- Eastern and southern Africa account for about 52% of the 40.8 million people living with HIV worldwide, Kenya has an HIV prevalence of 3.7%, and it signed a $2.5 billion bilateral health deal amid aid shifts under President Donald Trump's administration.
16 Articles
16 Articles
Kenya to roll out game-changing HIV drug in March
Kenya will begin rolling out a revolutionary new HIV-prevention drug in March, offering near-complete protection with just two shots a year. The move comes as African nations scramble to adapt to shifting US foreign aid priorities.
Kenya receives first 21,000 doses of injectable HIV‑prevention drug
The first phase, beginning in early March, will cover 15 counties including Mombasa, Kilifi, Machakos, Nairobi, Kajiado, Nakuru, Uasin Gishu, Kakamega, Busia, Siaya, Kisumu, Migori, Homa Bay, Kisii, and Kiambu.
Kenya Receives 21,000 Doses of Long-Acting HIV Prevention Drug Ahead of March Rollout
Nairobi -- Kenya has received an initial consignment of 21,000 starter doses of the long-acting injectable HIV prevention drug Lenacapavir, marking the first phase of a nationwide rollout set to begin in March 2026.
Lenacapavir, a 2-shot a year HIV prevention drug, lands in Kenya
The first shipment of Lenacapavir, a breakthrough HIV prevention drug, has landed in Kenya. Developed by the American biopharmaceutical company Gilead Sciences, Lenacapavir (marketed as Sunlenca) is a first-in-class capsid inhibitor. Unlike traditional Pre-Exposure Prophylaxis (PrEP), which often requires a daily pill, Lenacapavir is administered via subcutaneous injection just once every six months. This long-acting formula […] The post Lenacap…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
